Maze Therapeutics Inc MAZE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $31.99
- Day Range
- $31.45–33.16
- 52-Week Range
- $12.81–53.65
- Bid/Ask
- $31.79 / $34.20
- Shares Outstanding
- 55.35M
- Market Cap
- $1.79B
- Volume/Avg
- 584,905 / 728,314
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 80.94
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 141
- Website
- https://www.mazetx.com
Valuation
|
Metric
|
MAZE
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.78 |
Price/Sales | 80.94 |
Price/Cash Flow | — |
Price/Earnings
MAZE
Financial Strength
|
Metric
|
MAZE
|
|---|---|
Quick Ratio | 17.54 |
Current Ratio | 17.88 |
Interest Coverage | — |
Quick Ratio
MAZE
Profitability
|
Metric
|
MAZE
|
|---|---|
Return on Assets (Normalized) | −27.27% |
Return on Equity (Normalized) | −31.36% |
Return on Invested Capital (Normalized) | −31.78% |
Return on Assets
MAZE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|bTXMLmN | LOCK|jTrvw | $126B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|Vc!Nc@j | LOCK|Hb%V> | $70B | |||
| argenx SE ADR
ARGX
| LOCK|bT&$TD | LOCK|Q&& | $57B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|gT%@QW | LOCK|jnr> | $42B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|W&z<!& | LOCK|VN% | $35B | |||
| Moderna Inc
MRNA
| LOCK|S&jhSB$ | LOCK|^q? | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|!t^?Gkb | LOCK|tMfN | $26B | |||
| Incyte Corp
INCY
| LOCK|YBQ$^K | LOCK|%lp | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|ZDL<%c | LOCK|Bn | $24B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|Z>FC%T | LOCK|$pR | $18B |
United States